# Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

> **NCT00176488** · PHASE2 · TERMINATED · sponsor: **University of Medicine and Dentistry of New Jersey** · enrollment: 31 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** epirubicin
- **DRUG:** vinorelbine

## Key facts

- **NCT ID:** NCT00176488
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Competing studies
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00176488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00176488, "Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00176488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*